RILUTEK 50 MG
RILUZOLE : 50 MG · DIN 02242763 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is RILUTEK?
RILUTEK 50 MG contains RILUZOLE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02242763, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jan-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RILUTEK used for?
RILUTEK (riluzole) may extend survival and/or time to tracheostomy in some patients with amyotrophic lateral sclerosis (ALS). There is no evidence that RILUTEK exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. RILUTEK has not been shown to be effective in the late stage of ALS.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242763 |
|---|---|
| Brand name | RILUTEK |
| Generic / active ingredient | RILUZOLE : 50 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N07XX02 RILUZOLE |
| AHFS class | 28:44.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Jan-2007 |
| Original market date | 2000-10-26 00:00:00 |
How is it administered?
Recommended daily dosage is 100 mg/day (50 mg every 12 hours). Should be prescribed by physicians experienced in ALS management.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Contraindications
Hypersensitivity to riluzole; hepatic disease or baseline transaminases >3x ULN; pregnancy or breast-feeding.
Warnings and precautions
Risk of liver injury (monitor ALT monthly for 3 months, then periodically); risk of neutropenia (report febrile illness); risk of interstitial lung disease.
What can be used instead?
Other Canadian products sharing ATC code N07XX02 RILUZOLE. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-RILUZOLE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02352583 |
| MYLAN-RILUZOLE | 50 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02390299 |
Who else supplies RILUZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RILUZOLE appears in 52 registered pack listings across 11 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.